Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT05726227 · ClinicalTrials.gov registry record · Phase 3
A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight
A Phase 3 study of Obesity, sponsored by Novo Nordisk A/S.
- Active
- Registry status
- Phase 3
- Development phase
- 210
- Enrollment target
- 20
- Study locations
NCT05726227 is a Phase 3 study of Obesity that is active but no longer recruiting, run by Novo Nordisk A/S. The registered enrollment target is 210 participants, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (74% lower). The trial reports 20 study locations across 15 states.
The verdict
NCT05726227, a Phase 3 study of Obesity, is active but no longer recruiting, sponsored by Novo Nordisk A/S.
- ACTIVE NOT RECRUITING
- Registry status
- Phase 3
- Development phase
- 210 participants
- Enrollment target
- 20
- Study locations
Study Summary
This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the child's parent and the child will have talks with study staff about healthy food choices, how to be more physically active and what your child can do to try to lose weight. The child will either get semaglutide or a "dummy" medicine. Which treatment the child will get is decided by chance. Semaglutide is an approved medicine for type 2 diabetes and weight management in adults. The child will get one injection once a week. The study medicine is injected with a thin needle in the stomach, thighs or upper arms. The study will last for about 2 ½ years (132 weeks).
Conditions Studied
Interventions
- DRUG Placebo
- DRUG Semaglutide
Study Locations (20)
Louisiana
- Pennington Biom Res Ctr - Baton Rouge
- Clinical Trials of America LLC - Monroe
- IMA Clinical Research - Monroe
Georgia
- Columbus Research Foundation - Columbus
- Eastside Bariatric and Gen Surg - Snellville
Mississippi
- Mississippi Center for Advanced Medicine - Madison
- Mississippi CTR for ADV MED - Madison
Tennessee
- Vanderbilt University Medical Center - Nashville
- Tullahoma Pediatrics PLLC - Tullahoma
California
- Neighborhood Healthcare - Escondido
Connecticut
- Yale School of Medicine - New Haven
Idaho
- Solaris Clinical Research - Meridian
Maryland
- Barry J. Reiner, MD LLC - Baltimore
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 210 participants |
| Start Date | 2023-07-07 |
| Est. Completion | 2026-12-07 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT05726227
The ClinicalTrials.gov registry entry for NCT05726227 describes a study currently listed as active not recruiting, categorized as Phase 3. The registered enrollment target is 210 participants, a figure that helps gauge the scale of data the investigators plan to collect, below the 819-participant average among 1,053 other Obesity trials with a reported enrollment target (74% lower). The listed sponsor is Novo Nordisk A/S, which has 431 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Obesity appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.
NCT05726227 reports 20 study locations spanning 15 distinct geographic areas - top geographies include Louisiana, Georgia, Mississippi.
Frequently Asked Questions
What is clinical trial NCT05726227 about?
NCT05726227 is a clinical study titled "A Research Study on How Well Semaglutide Helps Children and Teenagers With Excess Body Weight Lose Weight". This study will look at how well semaglutide helps children and teenagers losing weight. This will be tested by comparing the effect on body weight in children and teenagers taking semaglutide in comparison to placebo, a "dummy" medicine. In addition to taking the medicine, the child's parent and th...
What is the current status of trial NCT05726227?
This trial is currently active not recruiting. It is a Phase 3 study. The enrollment target is 210 participants. The study started on 2023-07-07. Estimated completion is 2026-12-07.
What conditions does trial NCT05726227 study?
This clinical trial studies the following conditions: Obesity.
What interventions are being tested in trial NCT05726227?
The interventions under investigation include: Placebo (DRUG), Semaglutide (DRUG).
Who is sponsoring clinical trial NCT05726227?
This trial is sponsored by Novo Nordisk A/S, which has 431 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT05726227 being conducted?
This trial has 20 study locations across California, Connecticut, Georgia, Idaho, Louisiana. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Obesity
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
A Platform Trial for Pediatric Participants With Obesity or Overweight (LY900040)
RECRUITING · Phase 3
-
Efficacy and Safety of KAI-9531 Administered Once Weekly Compared With Semaglutide and Placebo in Participants Living With Obesity Who Do Not Have Diabetes
RECRUITING · Phase 3
-
A Study of Retatrutide (LY3437943) in Participants With Obesity or Overweight
RECRUITING · Phase 3
-
A Master Protocol for Orforglipron (LY3502970) in Participants With Obesity or Overweight With and Without Type 2 Diabetes
RECRUITING · Phase 3
-
A Research Study on How Well Cagrilintide and CagriSema Work in Children and Adolescents With Excess Body Weight
RECRUITING · Phase 3
-
A Study of Orforglipron (LY3502970) in Participants With Obesity or Overweight and at Least One Weight-Related Comorbidity
RECRUITING · Phase 3
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.